E-LIB Suche - Ergebnisse für: Miguel Bergua Burgues, Juan

1

S132: UPDATED RESULTS OF VEN-A-QUI STUDY: A PHASE 1-2 TRIAL..:

Miguel Bergua Burgues, Juan ; Rodríguez-Veiga, Rebeca ; Cano Ferri, Isabel...
HemaSphere. 7 (2023) S3 - p. e8385270 , 2023

Link: https://doi.org/10.1097/..

2

P498: INCIDENCE, RISK FACTORS AND OUTCOMES OF SECOND NEOPLA..:

Sobas, Marta ; Knopinska-Posluszny, Wanda ; Piątkowska-Jakubas, Beata...
HemaSphere. 7 (2023) S3 - p. e835897e , 2023

Link: https://doi.org/10.1097/..

3

P531: MIDOSTAURIN PLUS 7 + 3 OR QUIZARTINIB PLUS 7 + 3 IN F..:

Tormo, Mar ; Diaz-Beya, Marina ; Beneit, Paola...
HemaSphere. 7 (2023) S3 - p. e4025574 , 2023

Link: https://doi.org/10.1097/..

4

P492: SAFETY AND EFFICACY OF LP-108 AS MONOTHERAPY AND COMB..:

Koenig, Kristin ; Miguel Bergua Burgues, Juan ; Montesinos, Pau...
HemaSphere. 7 (2023) S3 - p. e2546261 , 2023

Link: https://doi.org/10.1097/..

5

ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphami..:

Flowers, Christopher ; Tilly, Hervé ; Morschhauser, Franck...
Clinical Lymphoma Myeloma and Leukemia. 22 (2022) - p. S358-S359 , 2022

Link: https://doi.org/10.1016/..

6

Poster: ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclop..:

Flowers, Christopher ; Tilly, Hervé ; Morschhauser, Franck...
Clinical Lymphoma Myeloma and Leukemia. 22 (2022) - p. S163 , 2022

Link: https://doi.org/10.1016/..

7

Oral Abstract: ABCL-073 Polatuzumab Vedotin Plus Rituximab,..:

Flowers, Christopher ; Tilly, Hervé ; Morschhauser, Franck...
Clinical Lymphoma Myeloma and Leukemia. 22 (2022) - p. S117 , 2022

Link: https://doi.org/10.1016/..

8

Targeting CD38 by isatuximab and a CD38/CD3xCD28 trispecifi..:

Martin-Sanchez, Esperanza ; Blanco Fernández, Laura ; Kim, Peter S....
Blood Advances. , 2024

Link: https://doi.org/10.1182/..

9

Clinical outcomes after CPX‐351 in patients with high‐risk ..:

Bernal, Teresa ; Moreno, Ainhoa Fernández ; de LaIglesia, Almudena...
Cancer Medicine. 12 (2023) 14 - p. 14892-14901 , 2023

Link: https://doi.org/10.1002/..

10

S130: PRELIMINARY RESULTS OF QUIWI: A DOUBLE BLINDED, RANDO..:

Montesinos, Pau ; Rodríguez-Veiga, Rebeca ; Bergua Burgues, Juan Miguel...
HemaSphere. 7 (2023) S3 - p. e734771d , 2023

Link: https://doi.org/10.1097/..

11

Extranodal natural killer/T‐cell lymphoma nasal type in a w..:

Gonzalez Barca, Eva ; Tomás‐Roca, Laura ; Esteve, Anna...
American Journal of Hematology. 98 (2023) 6 - p. , 2023

Link: https://doi.org/10.1002/..

12

Integrated flow cytometry and sequencing to reconstruct evo..:

Simoes, Catia ; Chillon, Maria-Carmen ; Martínez-Cuadrón, David...
Blood Advances. 7 (2023) 1 - p. 167-173 , 2023

Link: https://doi.org/10.1182/..

13

Safety and efficacy of tafasitamab with or without lenalido..:

Belada, David ; Kopeckova, Katerina ; Bergua Burgues, Juan Miguel...
Blood. 142 (2023) 16 - p. 1348-1358 , 2023

Link: https://doi.org/10.1182/..

14

S132: UPDATED RESULTS OF VEN-A-QUI STUDY: A PHASE 1-2 TRIAL..:

Miguel Bergua Burgues, Juan ; Rodríguez-Veiga, Rebeca ; Cano Ferri, Isabel...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428345/. , 2023

Link: http://www.ncbi.nlm.nih...

15

P531: MIDOSTAURIN PLUS 7 + 3 OR QUIZARTINIB PLUS 7 + 3 IN F..:

Tormo, Mar ; Diaz-Beya, Marina ; Beneit, Paola...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429514/. , 2023

Link: http://www.ncbi.nlm.nih...